Alterity Therapeutics Ltd (NAS:ATHE)
$ 1.95 -0.04 (-2.01%) Market Cap: 17.02 Mil Enterprise Value: 17.17 Mil PE Ratio: 0 PB Ratio: 0.59 GF Score: 37/100

Alterity Therapeutics Ltd at GCFF Global Chinese Financial Conference -- Healthcare Investment North America (Virtual) Transcript

Jun 16, 2022 / 03:30PM GMT
Release Date Price: $6.3 (+1.58%)
David Stamler
Alterity Therapeutics - CEO

Good morning, everyone. Thank you, Gilbert. Ni hao to our Chinese-speaking participants and thank you for the opportunity to present the great work that we're doing at Alterity Therapeutics. My name is David Stamler. I'm the CEO of Alterity. And I wanted to -- I look forward to telling you about the work that we're trying to -- that we're doing to help patients.

These are our forward-looking statements. And I'd advise you to consult our regulatory documents. As Gilbert mentioned, Alterity is dedicated to creating an alternate future for patients with neurodegenerative diseases. Now, our name itself, Alterity, means the state of being different. And we really want to change the arc of people's lives with these diseases and to modify the course of disease.

Our strategy is to target the underlying pathology of disease. And this is a common goal within neuro -- treating neurodegenerative diseases, but no one has been successful yet. We have a strong and highly experienced management team, including three drug approvals through the FDA. Our lead

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot